3626 results for «295»
3626 results
Treatment of paravalvular leak
21 Nov 2023 – From PCR London Valves 2023
Explore innovative approaches in paravalvular leak management with this selection of cases: discover the unique strategy of employing three plugs to close a challenging mitral paravalvular leak, navigate the challenges of tackling device migration and retrieval in the closure of a sizable aortic paravalvular leak, gain...
Mitral valve interventions in challenging clinical situations
21 Nov 2023 – From PCR London Valves 2023
Discover innovative approaches to mitral valve interventions in challenging clinical situations: navigate the challenges of critical stenosis in a bioprosthetic mitral valve, learn more about the use of iVAC-2L in transcatheter edge-to-edge repair for a mitral valve lacking leaflet coaptation, explore mitral transcutaneous edge-to-edge repair guided by transthoracic...
Second time TAVI (TAV-in-TAV) - Not as simple as it looks
19 Nov 2023 – From PCR London Valves 2023
Although it is still rare, TAV-in-TAV is likely to become more frequent, as TAVI is increasingly implanted in younger patients. Harmonizing data in this area will therefore help to improve outcomes, the quality of which depends on site experience, bearing in mind that for the time...
Impact of intravascular imaging guidance on percutaneous coronary intervention of severely calcified lesions: The ECLIPSE trial
29 Mar 2025
Aaysha Cader provides her take on the ECLIPSE trial presented by Gregg W. Stone at ACC.25 in Chicago.

Author
RADIANCE-HTN: Six-Month Outcomes of a Randomized Trial of Renal Denervation Versus a Sham Procedure for Resistant Hypertension – Impact of Treatment-Blinded Medication Titration
04 Nov 2021
Panos Xaplanteris review the RADIANCE-HTN Study, presented by Ajay Kirtane, an international randomized, sham-controlled clinical trial evaluating the safety and efficacy of renal denervation (RDN) in a population of treatment-resistant hypertensive patients.

Author
PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB: After revascularization of culprit lesions, assessment of coronary plaque size and composition matter!
17 Oct 2020
PROSPECT II, COMBINE (OCT–FFR) and PROSPECT ABSORB trials were presented at TCT Connect 2020. Hector Garcia-Garcia provides a summary of the key messages.

Author